Drug Trial Radar · NCT06679153
A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Nov 27, 2023
Primary completion
Dec 29, 2024
Study completion Dec 29, 2024
Sponsor
- Lead sponsor
- VivaVision Biotech, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at sites in the China in subjects with Noninfectious Anterior Uveitis
Conditions
- Anterior Uveitis
Interventions
VVN461 Ophthalmic Solution 1.0%Drug
VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
VVN461 Ophthalmic Solution 0.5%Drug
VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
Prednisolone acetateDrug
Prednisolone acetate, 1%, for up to 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACC score of ≥2 grade from baseline at Day 14Time frame: Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.